These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 31055792)
1. Population Pharmacokinetics of Sarilumab in Patients with Rheumatoid Arthritis. Xu C; Su Y; Paccaly A; Kanamaluru V Clin Pharmacokinet; 2019 Nov; 58(11):1455-1467. PubMed ID: 31055792 [TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetic-Pharmacodynamic Relationships of Sarilumab Using Disease Activity Score 28-Joint C-Reactive Protein and Absolute Neutrophil Counts in Patients with Rheumatoid Arthritis. Ma L; Xu C; Paccaly A; Kanamaluru V Clin Pharmacokinet; 2020 Nov; 59(11):1451-1466. PubMed ID: 32451909 [TBL] [Abstract][Full Text] [Related]
3. Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis. Bastida C; Ruiz-Esquide V; Pascal M; de Vries Schultink AHM; Yagüe J; Sanmartí R; Huitema ADR; Soy D Br J Clin Pharmacol; 2018 Apr; 84(4):716-725. PubMed ID: 29314183 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single-Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate. Paccaly AJ; Kovalenko P; Parrino J; Boyapati A; Xu C; van Hoogstraten H; Ishii T; Davis JD; DiCioccio AT J Clin Pharmacol; 2021 Jan; 61(1):90-104. PubMed ID: 32726514 [TBL] [Abstract][Full Text] [Related]
5. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Huizinga TW; Fleischmann RM; Jasson M; Radin AR; van Adelsberg J; Fiore S; Huang X; Yancopoulos GD; Stahl N; Genovese MC Ann Rheum Dis; 2014 Sep; 73(9):1626-34. PubMed ID: 24297381 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA. Abdallah H; Hsu JC; Lu P; Fettner S; Zhang X; Douglass W; Bao M; Rowell L; Burmester GR; Kivitz A J Clin Pharmacol; 2017 Apr; 57(4):459-468. PubMed ID: 27599663 [TBL] [Abstract][Full Text] [Related]
7. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis. Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318 [TBL] [Abstract][Full Text] [Related]
8. Differential Binding of Sarilumab and Tocilizumab to IL-6Rα and Effects of Receptor Occupancy on Clinical Parameters. Xu C; Rafique A; Potocky T; Paccaly A; Nolain P; Lu Q; Iglesias-Rodriguez M; St John G; Nivens MC; Kanamaluru V; Fairhurst J; Ishii T; Maldonado R; Choy E; Emery P J Clin Pharmacol; 2021 May; 61(5):714-724. PubMed ID: 33314148 [TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. Frey N; Grange S; Woodworth T J Clin Pharmacol; 2010 Jul; 50(7):754-66. PubMed ID: 20097931 [TBL] [Abstract][Full Text] [Related]
10. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Raimondo MG; Biggioggero M; Crotti C; Becciolini A; Favalli EG Drug Des Devel Ther; 2017; 11():1593-1603. PubMed ID: 28579757 [TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus. Narwal R; Roskos LK; Robbie GJ Clin Pharmacokinet; 2013 Nov; 52(11):1017-27. PubMed ID: 23754736 [TBL] [Abstract][Full Text] [Related]
12. Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis. Lee EB; Daskalakis N; Xu C; Paccaly A; Miller B; Fleischmann R; Bodrug I; Kivitz A Clin Pharmacokinet; 2017 Jun; 56(6):607-615. PubMed ID: 27722854 [TBL] [Abstract][Full Text] [Related]
13. Confirmatory Population Pharmacokinetic Analysis for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin-6, in Patients With Moderately to Severely Active Rheumatoid Arthritis. Xu Y; Hu C; Zhuang Y; Hsu B; Xu Z; Zhou H J Clin Pharmacol; 2018 Jul; 58(7):939-951. PubMed ID: 29578578 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies. Genovese MC; Fleischmann R; Kivitz A; Lee EB; van Hoogstraten H; Kimura T; St John G; Mangan EK; Burmester GR Arthritis Res Ther; 2020 Jun; 22(1):139. PubMed ID: 32522251 [TBL] [Abstract][Full Text] [Related]
15. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. Strand V; Kosinski M; Chen CI; Joseph G; Rendas-Baum R; Graham NM; van Hoogstraten H; Bayliss M; Fan C; Huizinga T; Genovese MC Arthritis Res Ther; 2016 Sep; 18(1):198. PubMed ID: 27600829 [TBL] [Abstract][Full Text] [Related]
16. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. Zhou H; Mayer PR; Wajdula J; Fatenejad S J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641 [TBL] [Abstract][Full Text] [Related]
17. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493 [TBL] [Abstract][Full Text] [Related]
18. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan. Tanaka Y; Wada K; Takahashi Y; Hagino O; van Hoogstraten H; Graham NMH; Kameda H Arthritis Res Ther; 2019 Mar; 21(1):79. PubMed ID: 30894208 [TBL] [Abstract][Full Text] [Related]
19. Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. Genovese MC; Fleischmann R; Kivitz AJ; Rell-Bakalarska M; Martincova R; Fiore S; Rohane P; van Hoogstraten H; Garg A; Fan C; van Adelsberg J; Weinstein SP; Graham NM; Stahl N; Yancopoulos GD; Huizinga TW; van der Heijde D Arthritis Rheumatol; 2015 Jun; 67(6):1424-37. PubMed ID: 25733246 [TBL] [Abstract][Full Text] [Related]
20. Association of High Serum Interleukin-6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis. Boyapati A; Schwartzman S; Msihid J; Choy E; Genovese MC; Burmester GR; Lam G; Kimura T; Sadeh J; Weinreich DM; Yancopoulos GD; Graham NMH Arthritis Rheumatol; 2020 Sep; 72(9):1456-1466. PubMed ID: 32343882 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]